Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: Percy Carter Clear advanced filters

    • PERCY E. NEWBERRY
    Comments & Opinion
    Nature
    Volume: 143, P: 507

  • The approval of first line immune checkpoint blockade (ICB) has improved outcomes for patients with metastatic non-small cell lung cancer (mNSCLC), however, whether patients would benefit more from ICB alone or alongside chemotherapy is unclear. Here, the authors develop a machine-learning based approach to help guide individual treatment selection patients with mNSCLC.

    • Maliazurina B. Saad
    • Qasem Al-Tashi
    • Jia Wu
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-11

  • Immune checkpoint inhibitors with or without chemotherapy are now standard of care for non-small cell lung cancer. However, the benefits of combination vs sequential therapy have not been fully explored. Here, the authors analysed 1,133 patient records and show combination therapy showed increased protection against early progression, but similar overall survival.

    • Lingzhi Hong
    • Muhammad Aminu
    • Natalie I. Vokes
    ResearchOpen Access
    Nature Communications
    Volume: 14, P: 1-15

  • Recent investments in nascent public biopharmaceutical companies indicate that companies focused on small-molecule approaches attracted more funding than might have been expected based on rates of return on investment compared with biologic approaches.

    • Percy H. Carter
    • Ernst R. Berndt
    • Mark Trusheim
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 15, P: 673-674